Literature DB >> 1375948

HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase.

F Brun-Vézinet1, D Ingrand, L Deforges, K Gochi, F Ferchal, M P Schmitt, M Jung, B Masquelier, J Aubert, C Buffet-Janvresse.   

Abstract

In order to select and standardize a reliable assay for the analysis of sensitivity of HIV isolates to AZT, we have compared two culture methods. The first assay (Cell-Associated Isolate Sensitivity Assay: CAISA) quantified AZT-resistant HIV isolates by end-point dilution cultures of peripheral blood mononuclear cells (PBMCs) in the presence of various concentrations of AZT. In the second assay (Cell-Free Isolate Sensitivity Assay: CFISA), following a conventional isolation of HIV, dilutions of infected cell-free supernatants were cultivated with fresh normal donor PBMCs in the presence of increasing concentrations of AZT. Samples from 64 untreated and AZT-treated patients were studied by CAISA (41), CFISA (43) or both assays (20). The CFISA, which allows the determination of titration parameters with respect to various kinetics patterns of viral replication was selected, and some of the CFISA phenotypically characterized isolates were further studied by nucleotide sequence analysis of the reverse transcriptase gene. CFISA showed that isolates from untreated patients were susceptible to AZT while the frequency of resistance increased with the duration of therapy. Genotypic analysis of CFISA-resistant isolates exhibited mutations at crucial positions, particularly at residue 215. We consider CFISA as a consensus culture technique for longitudinal studies of isolates from patients receiving AZT or other analogs of nucleosides.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375948     DOI: 10.1016/0166-0934(92)90045-f

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  12 in total

1.  In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.

Authors:  Benoit Visseaux; Charlotte Charpentier; Margarita Hurtado-Nedelec; Alexandre Storto; Romain Antoine; Gilles Peytavin; Florence Damond; Sophie Matheron; Françoise Brun-Vézinet; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

Authors:  D Descamps; G Collin; F Letourneur; C Apetrei; F Damond; I Loussert-Ajaka; F Simon; S Saragosti; F Brun-Vézinet
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility.

Authors:  C Apetrei; D Descamps; G Collin; I Loussert-Ajaka; F Damond; M Duca; F Simon; F Brun-Vézinet
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.

Authors:  S Yerly; A Rakik; S K De Loes; B Hirschel; D Descamps; F Brun-Vézinet; L Perrin
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy.

Authors:  R S Tedder; S Kaye; C Loveday; I V Weller; D Jeffries; J Norman; J Weber; M Bourelly; R Foxall; A Babiker; J H Darbyshire
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

6.  Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.

Authors:  C A Boucher; W Keulen; T van Bommel; M Nijhuis; D de Jong; M D de Jong; P Schipper; N K Back
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

7.  Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.

Authors:  H Sato; Y Tomita; K Shibamura; T Shiino; T Miyakuni; Y Takebe
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

8.  Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.

Authors:  N Yahi; J Fantini; K Mabrouk; C Tamalet; P de Micco; J van Rietschoten; H Rochat; J M Sabatier
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis.

Authors:  D Descamps; V Calvez; G Collin; A Cécille; C Apetrei; F Damond; C Katlama; S Matheron; J M Huraux; F Brun-Vézinet
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

10.  Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.

Authors:  P Kellam; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.